Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer to divide firm into three businesses

Executive Summary

Pfizer has unveiled plans to restructure the company into three business units, separating biosimilars, generics and OTC medicines. Biosimilars will be housed in the US firm’s ‘Innovative Medicines’ division, alongside a new hospital business unit for anti-infectives and sterile injectables; an ‘Established Medicines’ segment will incorporate “certain generics” with Pfizer’s off-patent solid oral-dose legacy brands, “operating with substantial autonomy within Pfizer”; and a ‘Consumer Healthcare’ division will include the company’s OTC medicines. The changes will come into effect at the start of 2019.

You may also be interested in...



Pfizer Deal Will Dramatically Reshape Mylan’s Model

Following the announcement of a merger between Mylan and Pfizer’s Upjohn, the top executive team that will take charge of the combination has set out its vision for the company.

Pfizer To Merge Off-Patent Business With Mylan

Pfizer has announced plans to merge its off-patent unit with Mylan, creating a new generics and biosimilars giant in the US.

Pfizer Eyes Three Oncology Biosimilar Launches In 2019 As Sterile Injectables Problems Persist

Pfizer’s long-standing sterile injectable supply and manufacturing issues pummelled respective sales in the US in 2018. But the US-based multinational is eyeing a string of oncology biosimilar launches in 2019, which could see biosimilar sales tick past US$1 billion.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB000975

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel